Literature DB >> 28643243

Toward predictive biomarkers of response to kinase inhibitor therapies in differentiated thyroid cancer.

Nicole M Iñiguez-Ariza1, Keith C Bible2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28643243     DOI： 10.1007/s12020-017-1342-1

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  5 in total

1.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Authors:  Marcia S Brose; Christopher M Nutting; Barbara Jarzab; Rossella Elisei; Salvatore Siena; Lars Bastholt; Christelle de la Fouchardiere; Furio Pacini; Ralf Paschke; Young Kee Shong; Steven I Sherman; Johannes W A Smit; John Chung; Christian Kappeler; Carol Peña; István Molnár; Martin J Schlumberger
Journal:  Lancet       Date:  2014-04-24       Impact factor: 79.321

2.  Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib.

Authors:  Vincenzo Marotta; Concetta Sciammarella; Mario Capasso; Alessandro Testori; Claudia Pivonello; Maria Grazia Chiofalo; Rosario Pivonello; Luciano Pezzullo; Gerardo Botti; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2016-12-16       Impact factor: 3.633

Review 3.  Evolving molecularly targeted therapies for advanced-stage thyroid cancers.

Authors:  Keith C Bible; Mabel Ryder
Journal:  Nat Rev Clin Oncol       Date:  2016-03-01       Impact factor: 66.675

4.  Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid.

Authors:  Makoto Tahara; Martin Schlumberger; Rossella Elisei; Mouhammed Amir Habra; Naomi Kiyota; Ralf Paschke; Corina E Dutcus; Taro Hihara; Shannon McGrath; Mark Matijevic; Tadashi Kadowaki; Yasuhiro Funahashi; Steven I Sherman
Journal:  Eur J Cancer       Date:  2017-02-24       Impact factor: 9.162

5.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Authors:  Martin Schlumberger; Makoto Tahara; Lori J Wirth; Bruce Robinson; Marcia S Brose; Rossella Elisei; Mouhammed Amir Habra; Kate Newbold; Manisha H Shah; Ana O Hoff; Andrew G Gianoukakis; Naomi Kiyota; Matthew H Taylor; Sung-Bae Kim; Monika K Krzyzanowska; Corina E Dutcus; Begoña de las Heras; Junming Zhu; Steven I Sherman
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.